158. Tuberous sclerosis
100 clinical trials,   62 drugs   (DrugBank: 16 drugs),   35 drug target genes,   115 drug target pathways

Searched query = "Tuberous sclerosis", "Tuberous sclerosis complex"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02849457
(ClinicalTrials.gov)
December 201613/7/2016Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis ComplexPreventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex (PREVeNT Trial) A Randomized, Double-blind, Placebo-controlled Seizure Prevention Clinical Trial for Infants With TSCTuberous Sclerosis ComplexDrug: Vigabatrin;Drug: PlaceboMartina BebinNational Institute of Neurological Disorders and Stroke (NINDS)Active, not recruitingN/A6 MonthsAll84Phase 2United States
2EUCTR2013-005528-40-BE
(EUCTR)
11/12/201417/11/2014Long-term, prospective study evaluating clinical and molecular biomarkers of epileptogenesis in a genetic model of epilepsy – tuberous sclerosis complexLong-term, prospective study evaluating clinical and molecular biomarkers of epileptogenesis in a genetic model of epilepsy – tuberous sclerosis complex - EPISTOP epilepsy in tuberous sclerosis complex (TSC);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: vigabatrin (sabril)
Product Name: vigabatrin
INN or Proposed INN: VIGABATRIN
Vrije Universiteit BrusselNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
100Belgium;Netherlands
3EUCTR2013-005528-40-NL
(EUCTR)
05/12/201414/07/2014Long-term, prospective study evaluating clinical and molecular biomarkers of epileptogenesis in a genetic model of epilepsy – Tuberous Sclerosis Complex.Long-term, prospective study evaluating clinical and molecular biomarkers of epileptogenesis in a genetic model of epilepsy – Tuberous Sclerosis Complex. - EPISTOP Epilepsy in tuberous sclerosis complex (TSC)
MedDRA version: 17.0;Level: LLT;Classification code 10032061;Term: Other forms of epilepsy;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Vigabatrin (Sabril)
Product Name: vigabatrin
The Children's Memorial Health InstituteNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
100Belgium;Netherlands
4NCT01266291
(ClinicalTrials.gov)
August 201022/12/2010Sabril for Complex Partial Seizures in Adult Tolerability Study (TS) PatientsSabril for Treatment of Adult Refractory Partial Seizures Symptomatic of Tuberous Sclerosis: An Open Label, Phase IV Prospective Safety and Tolerability StudyComplex Partial SeizuresDrug: vigabatrinUniversity of PennsylvaniaH. Lundbeck A/STerminated18 YearsN/AAll1Phase 4United States